Develops novel oral therapies for the treatment of gastrointestinal and respiratory diseases, aiming to enhance patient adherence and therapeutic effectiveness.
Eupraxia Pharmaceuticals Inc. is an innovative biotechnology company in the clinical stage, dedicated to advancing discoveries, developments, and technologies within the biotechnology sector.
At the forefront of its portfolio are several promising product candidates. EP-104IAR is currently undergoing a Phase III clinical trial, aimed at addressing critical unmet medical needs and providing pain relief for knee osteoarthritis patients. Simultaneously, EP-104GI is progressing through Phase II trials, targeting eosinophilic esophagitis, while EP-104 is undergoing preclinical studies for treating inflammatory joint conditions, benign esophageal strictures, and exploring epidural delivery applications.
Beyond these advancements, Eupraxia Pharmaceuticals is actively engaged in the development of additional product candidates for oncology, underscoring its commitment to broadening therapeutic options across multiple disease areas. Originally known as Plaza Capital Partners Inc., the company rebranded to Eupraxia Pharmaceuticals Inc. in May 2012. Headquartered in Victoria, Canada, Eupraxia Pharmaceuticals was founded in 2011 and continues to drive innovation in biotechnology with a focus on transformative treatments for complex medical conditions.